Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Abstract Background While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood....

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yukiko Kiniwa, Kenta Nakamura, Asuka Mikoshiba, Atsuko Ashida, Yasuyuki Akiyama, Atsushi Morimoto, Ryuhei Okuyama
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-03-01
coleção:	BMC Cancer
Assuntos:	BRAF Circulating tumor cell Melanoma BRAF/MEK inhibitor Heterogenous mutation
Acesso em linha:	https://doi.org/10.1186/s12885-021-08016-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!